Torrent Pharmaceuticals Limited vs Gland Pharma Limited
An objective side-by-side of TORNTPHARM and GLAND, both in Pharmaceuticals - Indian - Formulations: valuation, profitability, growth, balance sheet, ownership and share-price performance. Where one number is clearly better on its own terms (lower P/E, higher ROE), it is shaded. That is a description, not a recommendation.
Prices as of 2026-11-05 close
Latest results: TORNTPHARM Sep 2026 · GLAND Jun 2026
At a glance
- Torrent Pharmaceuticals Limited is the larger company by market value, about 3.5 times the size of Gland Pharma Limited.
- On trailing earnings, Gland Pharma Limited trades at the lower P/E (46.0 against 85.4).
- Torrent Pharmaceuticals Limited earns the higher return on equity (25.0% against 10.9%).
- Over three years Torrent Pharmaceuticals Limited has grown profits faster (22% a year against 8%).
- Over the past year the share prices returned +30.8% (TORNTPHARM) and +65.0% (GLAND).
| Metric | Torrent Pharmaceuticals TORNTPHARM |
Gland Pharma GLAND |
|---|---|---|
| Size and price | ||
| Market cap | ₹179,153 Cr | ₹51,899 Cr |
| Share price | ₹4,710.00 | ₹3,145.20 |
| Valuation | ||
| P/E | 85.35 | 45.96 |
| P/B | 21.36 | 5.01 |
| EV/EBITDA | 33.63 | 29.80 |
| PEG | 3.88 | 5.75 |
| Dividend yield | 0.8% | 0.6% |
| Profitability | ||
| ROE | 25.0% | 10.9% |
| ROCE | 15.0% | 15.0% |
| Operating margin | 33.2% | 26.0% |
| Sales (TTM) | ₹17,400 Cr | ₹6,726 Cr |
| Net profit (TTM) | ₹2,099 Cr | ₹1,129 Cr |
| Growth | ||
| Latest quarter sales YoY | +50.8% | +19.6% |
| Latest quarter profit YoY | -9.6% | +47.1% |
| Sales CAGR 3Y | +13.0% | +21.0% |
| Profit CAGR 3Y | +22.0% | +8.0% |
| Sales CAGR 5Y | +12.0% | +13.0% |
| Profit CAGR 5Y | +12.0% | +1.0% |
| Financial strength | ||
| Debt/Equity | 1.79 | 0.03 |
| Interest cover | 8.94 | 36.26 |
| Ownership | ||
| Promoter holding | 60.8% | 45.8% |
| Promoter change (4 qtrs) | -7.53 pp | -6.08 pp |
| Price performance | ||
| Return 1M | -1.30% | +4.63% |
| Return 3M | -5.80% | +23.58% |
| Return 1Y | +30.75% | +65.03% |
| Return YTD | +22.34% | +82.65% |
| Technical condition | ||
| Technical score | 72 | 78 |
| RS rating (1-99) | 74.00 | 94.00 |
| % vs 200-DMA | +4.10% | +36.60% |
| RSI (14) | 52.87 | 61.55 |
| % from 52-week high | -10.29% | -1.98% |
